This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The two interventions were 10mg ezetimibe plus 40mg simvastatin versus remaining on a statin at double the original dose. The original statin doses were at three levels low potency (fluvastatin 40mg, pravastatin 10mg or 20mg, or simvastatin 10mg), medium potency (atorvastatin 10mg or simvastatin 20mg), and high potency (atorvastatin 20mg or 40mg, rosuvastatin 10mg or 20mg, or simvastatin 40mg).
Location/setting
UK/primary care.
Methods

Analytical approach:
The economic evaluation was based on a Markov model with a lifetime horizon. The authors stated that the analysis was conducted from the perspective of the payer (the UK Department of Health).
Effectiveness data:
The bulk of the clinical evidence came from the INFORCE study, a multicentre, multi-country, randomised, controlled trial (RCT) with a 12-week time horizon and a sample of 384 patients who had received a suboptimal statin dose and who were either switched to ezetimibe/simvastatin or had their statin dose doubled. The primary endpoint was the reduction in lipid levels with these two options. These data were used in the Markov model to project the long-term risk of coronary heart disease (CHD), using Framingham risk equations. The death rates not related to ACS, were from the UK Office for National Statistics.
Monetary benefit and utility valuations:
The utility values were from a published pharmacoeconomic model.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 3.5%.
